Latest News and Press Releases
Want to stay updated on the latest news?
-
LEXINGTON, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative diagnostic products for critical...
-
LEXINGTON, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced the pricing of an underwritten registered public offering of 6,100,000 shares of common stock at...
-
LEXINGTON, Mass., May 29, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (Nasdaq:TTOO), an emerging leader in the development and commercialization of innovative diagnostic products for critical unmet...
-
First FDA-cleared test to identify sepsis-causing bacteria direct from whole blood Cuts time to diagnosis from days to hours, allowing greater certainty and new protocols for deadly infections in...
-
Quarterly Product Revenue Up 66% Year-Over-Year On Track for Potential FDA Clearance of T2Bacteria Panel in the Second Quarter 2018 LEXINGTON, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- T2...
-
LEXINGTON, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for...
-
LEXINGTON, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for...
-
LEXINGTON, Mass., April 04, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for...
-
LEXINGTON, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products,...
-
LEXINGTON, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for...